Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (1): 45-49.doi: 10.6040/j.issn.1671-7554.0.2017.1025

Previous Articles    

Efficacy and safety of single-agent domestic docetaxel in the treatment of advanced breast cancer

LÜ Huimin, ZHANG Mengwei, NIU Limin, ZENG Huiai, YAN Min   

  1. Diagnosis and Treatment Center for Breast Cancer, Affiliated Cancer Hospital of Zhengzhou University &
    Henan Cancer Hospital, Zhengzhou 450008, Henan, China
  • Published:2022-09-27

PDF (PC)

21

Abstract: Objective To observe the efficacy and toxicities of domestic docetaxel single-agent chemotherapy in the treatment of advanced breast cancer. Methods A total of 141 patients with advanced breast cancer treated with domestic docetaxel were reviewed every 2 cycles of treatment. The objective response rate(ORR), time to progress(TTP), time to treatment failure(TTF), toxicity and adverse responses were evaluated. The effects of dexamethasone dosage on the safety of chemotherapy were observed. Results The median number of treatment was 6(1~14)cycles. Of all 141 cases, none were complete remission(CR), 62 were partial remission(PR), 61 were stable disease(SD), and 18 were progression disease(PD). The ORR was 43.0%(62/141), clinical benefit rate(CBR)was 51.8 %(73/141), disease control rate(DCR)was 87.2%(123/141), TTP was 6.5(5.8~7.2)months, and TTF was 4.0(3.9~4.1)months. The grade 3~4 adverse reactions included neutropenia(72.3%), abdominal pain and diarrhea(2.8%)and oral mucositis(4.3%), which were relieved after symptomatic treatment. Reducing the dosage of dexamethasone did not increase adverse reactions. Conclusion Single-agent domestic docetaxel showed good efficacy and safety for patients with advanced breast cancer. The dosage of dexamethasone can be reduced for those who could not tolerate adverse reactions caused by corticosteroid.

Key words: Domestic docetaxel, Advanced breast cancer, Efficacy, Safety, Chemotherapy

CLC Number: 

  • R737.9
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
[2] Early Breast Cancer Trialists Collaborative Group(EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials[J]. Lancet, 2005, 365(9472): 1687-1717.
[3] Cardoso F, Costa A, Senkus E, et al. 3rd ESMO International Consensus Guidelines for Advanced Breast Cancer(ABC 3)[J]. Ann Oncol, 2017, 28(1): 16-33.
[4] Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer[J]. Cochrane Database Syst Rev, 2009, 2(2). Doi:10.1002/14651858.CD-003372 pub3.
[5] Seidman AD, Tiersten A, Hudis C, et al. Phase Ⅱ trial of paclitaxel by 3- hour infusion as initial and salvage chemotherapy for metastatic breast cancer[J]. J Clin Oncol, 1995, 13(10): 2575-2581.
[6] Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer[J]. J Clin Oncol, 2001, 19(22): 4216-4223.
[7] Rd BH. Single-agent docetaxel(Taxotere)in randomized phase III trials[J]. Semin Oncol, 1999, 26(9): 1-6.
[8] Eisenhauer EA,Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[9] National Cancer Institute. Common Terminology Criteria for Adverse Events v.4.0(CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed June 14, 2011.
[10] Nabholtz JM, Tonkin K, Smylie M, et al. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?[J]. Expert Opin Pharmaco, 2000, 1(2): 187-206.
[11] Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines[J]. Cancer Chemother Pharmacol, 1992, 30(6): 444-450.
[12] Harvey V, Mouridsen H, Semiglazov V, et al. Phase Ⅲ trial comparing three doses of docetaxel for second-1ine treatment of advanced breast cancer[J]. J Clin Oncol, 2006, 24(31): 4963-4970.
[13] Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer[J]. Drugs, 2000, 59(3): 621-651.
[14] 王子平, 孙燕, 张湘茹, 等. 多西他赛治疗晚期乳腺癌的临床研究[J]. 中华肿瘤杂志, 2006, 28(6): 468-470. WANG Ziping, SUN Yan, ZHANG Xiangru, et al. Docetaxel in the treatment of advanced breast cancer[J]. Chinese Journal of Oncology, 2006, 28(6): 468-470.
[15] Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23(19): 4265-4274.
[16] Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer[J]. J Clin Oncol, 2005, 23(24): 5542-5551.
[17] Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy[J]. J Clin Oncol, 1999, 17(5): 1413-1424.
[18] Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure[J]. Br J Cancer, 2002, 87(11): 1210-1215.
[19] Sjöström J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group[J]. Eur J Cancer, 1999, 35(8): 1194-1201.
[20] Brodowicz T, Koestler WJ, Tomek S, et al. Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer[J]. Anti-Cancer Drugs, 2000, 11(3): 149-153.
[21] Bergh M, Magnusson K, Nilsson JL, et al. Contact allergenic activity of Tween 80 before and after air exposure[J]. Contact Dermatitis,1997, 37: 9-18.
[22] Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment[J]. J Clin Oncol, 1998, 16(10): 3426-3432.
[23] Schwartz JR. Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly?[J]. J Oncol Pharm Practice, 2012, 18(2): 250-256.
[24] Chouhan JD, Herrington JD. Single premedication dose of dexamethasone 20 mg IV before docetaxel administration[J]. J Oncol Pharm Practice, 2010, 17(3): 155-159.
[25] 李海志, 徐沁甜, 宋毕清. 单次剂量地塞米松10 mg静注预防多西他赛副反应的安全性与可行性研究[J]. 中国现代医药杂志, 2016, 18(8): 63-64.
[1] RUAN Xiangyan, CHENG Jiaojiao, DU Juan, GU Muqing. Ovarian tissue cryopreservation and preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 24-30.
[2] MA Xiang, ZHAO Feiyan. Status and progress of oocyte cryopreservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 19-23.
[3] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[4] Zhuxiu CHU,Wenjing ZHAO,Xiaoyan LI,Xiaoli KONG,Tingting MA,Liyu JIANG,Qifeng YANG. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139.
[5] Hongling WEN,Xiaoying XU. Prevention and control of emerging viral infectious diseases and biosafety [J]. Journal of Shandong University (Health Sciences), 2021, 59(5): 40-45.
[6] MIAO Zhuang, LIU Peilai, LU Qunshan, YAO Tianxiao, LI Songlin, LUO Desu. Early efficacy of double-column mobile bearing unicompartmental knee prosthesis in treating medial knee osteoarthritis [J]. Journal of Shandong University (Health Sciences), 2021, 59(5): 90-95.
[7] LUO Yingshu, LI Bin, XU Changqin, JIANG Junmei, XU Hongwei. Evaluation of the efficacy and complications of endoscopic treatment of 240 cases of upper gastrointestinal submucosal tumors [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 74-80.
[8] LIN Yuxi, LI Chuanxi, WANG Lin, MA Wei. Sexual orientation disclosure and HIV testing uptake among men who have sex with men: chain mediating effect of HIV testing social norms and self-efficacy [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 113-119.
[9] JIA Jianhua, CHEN Si, WU Qianqian, XU Shuo, LI Chao, CHENG Lian, XU Shujun. Efficacy of SEEG-guided radiofrequency thermocoagulation in patients with medically intractable epilepsy [J]. Journal of Shandong University (Health Sciences), 2021, 59(10): 80-86.
[10] LU Cuiyan, PAN Fang, FANG Fang. Relationship between active or passive procrastination and mindfulness, and self-efficacy of college students [J]. Journal of Shandong University (Health Sciences), 2021, 59(10): 108-113.
[11] XIAO Juan, XIAO Qiang, CONG Wei, LI Ting, DING Shouluan, ZHANG Yuan, SHAO Chunchun, WU Mei, LIU Jianing, JIA Hongying. Comparison of diagnostic efficacy of two kinds of thyroid imagine reporting and data systems [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 53-59.
[12] ZHANG Xiqin, ZHU Shouhui, LIU Ning, WANG Yu, CHEN Jiazhen, HU Xudong. Clinical observation of PEG-rhG-CSF in preventing neutropenia in 80 patients with small cell lung cancer treated with concurrent chemoradiotherapy [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 43-46.
[13] CHEN Bo, ZHANG Lei. Current perspectives of neoadjuvant therapy for breast cancer in 2017 [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 12-16.
[14] SHI Aiping, XU Gege, XIE Xinpeng. Review of neoadjuvant therapy for breast cancer at the St.Gallen conference [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 6-11.
[15] WANG Shu, PENG Yuan. Treatment of early breast cancer: more or less? Study from the 2017 American Society of Clinical Oncology Annual Meeting [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 17-21.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd